On the other hand, the use of bisphosphonates for the treatment of osteoporosis is low even among super-elderly patients, and the use of osteoanabolic agents and anti-RANKL antibodies, which are more effective in the treatment of osteoporosis than bisphosphonates [29, 30], is also low, suggesting that the treatment of osteoporosis is not yet sufficiently widespread. Here, TNFSF11 is linked to osteoporosis.